Differential behavioral responses of the spontaneously hypertensive rat to methylphenidate and methamphetamine: Lack of a rewarding effect of repeated methylphenidate treatment

Neuroscience Letters

Volumn 514, Issue 2, 2012, Pages 189-193

  Peña, Ike Dela ^a   Lee, Jong Chan ^b   Lee, Han Lim ^a   Woo, Tae Seon ^a   Lee, Hae Chang ^a   Sohn, Aee Ree ^a   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Conditioned place preference; Methamphetamine; Repetitive methylphenidate; SHR; Wistar rat

Indexed keywords

METHAMPHETAMINE; METHYLPHENIDATE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; MALE; METHAMPHETAMINE; METHYLPHENIDATE; RATS; RATS, INBRED SHR; RATS, WISTAR; REWARD;

EID: 84862802580     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.02.090     Document Type: Article

References (51)

1. Accardio P., Blondis T.A. What's the fuss about Ritalin?. J. Pediatr. 2001, 138:6-9.
2. Arnsten A. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006, 31:2376-2383.
3. Arnsten A., Dudley A. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav. Brain Funct. 2005, 1:1-2.
4. Bardo M., Valoney J., Bevins R. Locomotion and conditioned place preference produced by acute intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine self-administration. Psychopharmacology (Berlin) 1999, 143:39-46.
5. J.Biederman J., Wilens T., Mick E., Faraone S.V., Weber W., Curtis S., Thornell A., Pfister K., Jetton J., Soriano J. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J. Am. Acad. Child Adolesc. Psychiatr. 1997, 36:21-29.
6. Dalley J.W., Theobald D.E., Cerry D., Milstein J.A., Laane K., Everitt B.J., Robbins T.W. Cognitive sequelae of intravenous amphetamine self-administration in rats: evidence for selective effects on attentional performance. Neuropsychopharmacology 2005, 30:525-537.
7. dela Peña I.C., Ahn H.S., Choi J.Y., Shin C.Y., Ryu J.H., Cheong J.H. Reinforcing effects of methamphetamine in an animal model of attention-deficit/hyperactivity disorder-the spontaneously hypertensive rat. Behav. Brain Funct. 2010, 6:72.
8. dela Peña I.C., Ahn H.S., Choi J.Y., Shin C.Y., Ryu J.H., Cheong J.H. Methylphenidate self-administration and conditioned place preference in an animal model of attention deficit hyperactivity disorder-the spontaneously hypertensive rat. Behav. Pharmacol. 2011, 22:31-39.
9. dela Peña I.C., Ahn H.S., Shin C.Y., Ryu J.H., Park I.H., Cheong J.H. Conditioned place preference studies with atomoxetine in an animal model of ADHD: effects of previous atomoxetine treatment. Eur. J. Pharmacol. 2011, 667:238-241.
10. I.C. dela Peña, S.Y. Yoon, J.C. Lee, J.B. dela Peña, A.R. Sohn, J.H. Ryu, C.Y. Shin, J.H. Cheong, Methylphenidate treatment in spontaneously hypertensive rat: influence on methylphenidate self-administration and reinstatement in comparison with Wistar rats, Psychopharmacology, in press. doi:10.1007/s00213-011-2564-1.
11. Dommet E., Henderson E., Westwell M. Methylphenidate amplifies long-term plasticity in the hippocampus via noradrenergic mechanisms. Learn. Mem. 2008, 15:580-586.
12. Feldman R.S., Meyer J.S., Quenzer L.F. Stimulants: Amphetamine and Cocaine (Principles of Neuropsychopharmacology) 1997, Sinauer, Sunderland, MA.
13. Fletcher P.J., Korth K.M., Stewart J., Chambers J.W. Depletion of brain serotonin following intra-raphe injections of 5,7-dihydroxytryptamine does not alter d-amphetamine self-administration across different schedules and access conditions. Psychopharmacology (Berlin) 1999, 146:185-193.
14. Gatley S.J., Meehan S.M., Chen R., Pan D.F., Schechter M.D., Dewey S.L. Place preference and microdialysis studies with two derivatives of methylphenidate. Life Sci. 1996, 58:PL345-PL352.
15. Gehrke B.J., Harrod S.B., Cass W.A., Bardo M.T. The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats. Psychopharmacology 2003, 166:249-257.
16. Haile C.N., Kosten T.R., Kosten T.A. Pharmacogenetic treatments for drug addiction:cocaine, amphetamine and methamphetamine. Am. J. Drug Alcohol Abuse 2009, 35(3):161-177.
17. Heal D.J., Cheetham S.C., Smith S.L. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009, 57:608-618.
18. Jaffe C., Bush K., Straits-Troster K., Meredith C. A comparison of methamphetamine-dependent inpatients with and without childhood attention deficit hyperactivity disorder symptomatology. J. Addict. Dis. 2008, 24(3):133-152.
19. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatr. 2005, 162:1403-1413.
20. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynauld M., Bakti S. Pharmacological approaches to methamphetamine dependence: a focused review. Br. J. Clin. Pharmacol. 2009, 69(6):578-592.
21. Kish S.J. Pharmacological mechanisms of crystal meth. CMAJ 2008, 178(13):1679-1682.
22. Kollins S.H. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychiatr. 2003, 64:14-18.
23. Kollins S.H. ADHD Substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J. Attent. Disord. 2008, 12:115-212.
24. Kuczenski R., Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 2001, 296:876-883.
25. Kuczenski R., Segal D.S. Stimulant action in rodents: implication for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol. Psychiatr. 2005, 57:1391-1396.
26. LeBlanc-Duchin D., Taukulis H. Chronic oral methylphenidate administration to periadolescent rats yields prolonged impairment of memory for objects. Neurobiol. Learn. Mem. 2007, 88:312-320.
27. Marco E.M., Adriani W., Ruocco L.A., Canese R., Sadile A.G., G.Laviola G. Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neurosci. Biobehav. Rev. 2011, 35:1722-1739.
28. Murray J.B. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 1998, 132:227-237.
29. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 1997, 25:192-216.
30. Robbins T.W. ADHD and addiction. Nat. Med. 2002, 8:24-25.
31. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 1997, 17:8491-8497.
32. Russell V.A., de Villiers A.S., Sagvolden T., Lamm M.C., Taljaard J.J. Methylphenidate affects striatal dopamine differently in an animal model for attention deficit/hyperactivity disorder-the spontaneously hypertensive rat. Brain Res. Bull. 2000, 53:187-192.
33. Sagvolden T., Johansen E.B., Wøien G., Walaas S.I., Storm-Mathisen J., Bergersen L.H., Hvalby O., Jensen V., Aase H., Russell V.A., Kileen P.R., Dasbanerjee T., Middleton F.A., Faraone S.V. The spontaneously hypertensive rat model of ADHD-the importance of selecting the appropriate reference strain. Neuropharmacology 2009, 57:619-626.
34. Sagvolden T., Russell V.A., Aase H., Johansen E.B., Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatr. 2005, 57:1239-1247.
35. Scherer E., da Cunha M., Matte C., Schmitz F., Netto C., Wyse A. Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol. Learn. Mem. 2010, 94:247-253.
36. Schiffer W.K., Volkow N.D., Fowler J.S., Alexoff D.L., Logan J., Dewey S.L. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006, 59:243-251.
37. Sim T., Simon S.L., Domier C.P., Richardson K., Rawson R.A., W.Ling W. Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J. Addict. Dis. 2002, 21(1):75-78.
38. Spear L.P., Brake S.C. Periadolescence age: age-dependent behavior and psychopharmacological responsivity in rats. Dev. Psychobiol. 1983, 16:83-109.
39. Suzuki T., Shindo K., Miyatake M., Kurokawa K., Higashiyama K., Suzuki M., Narita M. Lack of developmental development of behavioral sensitization to methylphenidate in mice: correlation with reversible astrocytic activation. Eur. J. Pharmacol. 2007, 574:39-48.
40. U.S. Food and Drug Administration FDA Drug Safety Communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in children and young adults, http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm.
41. Vendruscolo L.F., Izidio G.S., Takahashi R.N. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder- the spontaneously hypertensive rat (SHR). Curr. Drug Abuse Rev. 2009, 2:177-183.
42. Volkow N.D., Ding Y.S., Fowler J.S. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatr. 1995, 52:456-463.
43. Volkow N.D., Insel T.R. What are the long-term effects of methylphenidate treatment?. Biol. Psychiatr. 2003, 54:1307-1309.
44. Whitehorn D., Atwater D., Low W., Gellis J., Hendley E. Independence of blood pressure and locomotor hyperactivity in normotensive and genetically hypertensive rat. Behav. Neural Biol. 1983, 37:357-361.
45. Wilens T.E. Impact of ADHD and its treatment on substance abuse in adults. J. Clin. Psychiatr. 2004, 65:38-45.
46. Wilens T.E., Adler L.A., Adams J., Sgambati S., Rotrosen J., Sawtelle R., Utzinger L., Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatr. 2008, 47:21-31.
47. Wilens T.E., Faraone S.V., Biederman J., Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
48. Wise R.A., Hoffman D.C. Localization of drug reward mechanisms by intracranial injections. Synapse 1992, 10:247-263.
49. Yano M., Steiner H. Methylphenidate and cocaine: the same effects on gene regulation?. Trends Pharmacol. Sci. 2007, 28:588-596.
50. Yang P., Behrang A., Swann A., Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res. 2003, 971:139-152.
51. Yang P., Cuellar D., Swann A., Dafny N. Age and genetic strain differences in response to chronic methylphenidate administration. Behav. Brain Res. 2011, 218:206-217.